Document Detail


Cost-effectiveness of colonoscopy in screening for colorectal cancer.
MedLine Citation:
PMID:  11033584     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy are used to screen patients for colorectal cancer. OBJECTIVE: To compare the cost-effectiveness of fecal occult blood testing, flexible sigmoidoscopy, and colonoscopy. DESIGN: The cost-effectiveness of the three screening strategies was compared by using computer models of a Markov process. In the model, a hypothetical population of 100 000 persons 50 years of age undergoes annual fecal occult blood testing, sigmoidoscopy every 5 years, or colonoscopy every 10 years. Positive results on fecal occult blood testing or adenomatous polyps found during sigmoidoscopy are worked up by using colonoscopy. After polypectomy, colonoscopy is repeated every 3 years until no polyps are found. DATA SOURCES: Transition rates were estimated from U.S. vital statistics and cancer statistics and from published data on the sensitivity, specificity, and efficacy of various screening techniques. Costs of screening and cancer care were estimated from Medicare reimbursement data. TARGET POPULATION: Persons 50 years of age in the general population. TIME HORIZON: The study population was followed annually until death. PERSPECTIVE: Third-party payer. OUTCOME MEASURE: Incremental cost-effectiveness ratio. RESULTS OF BASE-CASE ANALYSIS: Compared with colonoscopy, annual screening with fecal occult blood testing costs less but saves fewer life-years. A screening strategy based on flexible sigmoidoscopy every 5 or 10 years is less cost-effective than the other two screening methods. RESULTS OF SENSITIVITY ANALYSIS: Screening with fecal occult blood testing is more sensitive to changes in compliance rates, and it becomes easily dominated by colonoscopy under most conditions assuming less than perfect compliance. Other assumptions about the sensitivity and specificity of fecal occult blood testing, screening frequency, efficacy of colonoscopy in preventing cancer, and polyp incidence have a lesser influence on the differences in cost-effectiveness between colonoscopy and fecal occult blood testing. CONCLUSIONS: Colonoscopy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs. Low compliance rates render colonoscopy every 10 years the most cost-effective primary screening strategy for colorectal cancer.
Authors:
A Sonnenberg; F Delcò; J M Inadomi
Related Documents :
8036464 - Results of screening, rescreening, and follow-up in a prospective randomized study for ...
18783684 - Endoscopic requirements of colorectal cancer screening programs in average-risk populat...
8637834 - Colorectal cancer screening: present strategies and future prospects.
21085544 - Eight years of colonoscopic bowel cancer screening in germany: initial findings and pro...
16094624 - Preschool diet and adult risk of breast cancer.
25335904 - Does labelling a rare cancer diagnosis 'good' affect the patient's experience of treatm...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of internal medicine     Volume:  133     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-10-26     Completed Date:  2000-10-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  573-84     Citation Subset:  AIM; IM    
Affiliation:
Gastroenterologie, Kantonsspital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Colonoscopy / economics*
Colorectal Neoplasms / diagnosis,  mortality,  prevention & control*
Computer Simulation
Cost-Benefit Analysis
Costs and Cost Analysis
Follow-Up Studies
Humans
Markov Chains
Mass Screening / economics*,  methods
Medicare
Middle Aged
Occult Blood*
Outcome Assessment (Health Care)
Patient Compliance
Sensitivity and Specificity
Sigmoidoscopy / economics*
United States
Comments/Corrections
Comment In:
Ann Intern Med. 2000 Oct 17;133(8):647-9   [PMID:  11033594 ]
Ann Intern Med. 2001 Aug 7;135(3):219   [PMID:  11487493 ]
Ann Intern Med. 2001 Aug 7;135(3):218-9; author reply 219   [PMID:  11487492 ]
Ann Intern Med. 2001 Aug 7;135(3):218; author reply 219   [PMID:  11487491 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A small sample confidence interval approach to assess individual bioequivalence.
Next Document:  Smoking is related to albuminuria and abnormal renal function in nondiabetic persons.